All News

22 September 2009

Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer PatientsAntibodies

21 September 2009

Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone MetastasesAntibodies

21 September 2009

Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid TumorsAntibodies

18 September 2009

ArmaGen completes primate safety study for AGT-181Antibodies

18 September 2009

Pancreatic and Colorectal Cancer Novel Antibody Developed from a Vaccine to Begin Phase I TrialAntibodies

17 September 2009

ImmunoGen Announces Amgen has Licensed Rights to Use the Company’s TAP Technology for a Solid Tumor TargetAntibodies

17 September 2009

Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for MaintenanceAntibodies

17 September 2009

Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics for novel treatments for oncology indicationsAntibodies

16 September 2009

Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral MucositisAntibodies

15 September 2009

Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)Antibodies

15 September 2009

Kenta Biotech Reports Phase IIa Data with Lead Candidate Panobacumab in Hospital-Acquired PneumoniaAntibodies

14 September 2009

Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer DiscontinuedAntibodies

11 September 2009

Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial DataAntibodies

9 September 2009

XOMA Announces $6 Million Antibody Discovery Collaboration With Arana TherapeuticsAntibodies

9 September 2009

ImmunoCellular Therapeutics Enters into Research and License Option Agreement with Roche GroupAntibodies

8 September 2009

MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering PharmaAntibodies

7 September 2009

Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License ApplicationAntibodies

4 September 2009

FDA Approves ZEVALIN(R) Expanded Label as Part of First-Line Therapy in Treatment of Follicular Non-Hodgkin’s LymphomaAntibodies

3 September 2009

Two New Antibodies Found to Cripple HIVAntibodies

3 September 2009

MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemiaAntibodies

2 September 2009

Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine’s Cotara(R) for Treatment of Brain CancerAntibodies

1 September 2009

Ablynx Initiates Phase II Clinical Trial for Alx-0081Antibodies

1 September 2009

Patient recruitment in Phase III registration trial with REDECTANE® successfully completedAntibodies

28 August 2009

Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016Antibodies

27 August 2009

START OF THE FIRST PHASE II CLINICAL TRIAL WITH MONOCLONAL ANTIBODY IPH 2101 SUPPORTED BY A NEW 2.9 MILLIONS EUROS FINANCING FROM OSEOAntibodies

27 August 2009

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)Antibodies

26 August 2009

Dyax Announces Developments in Licensing and Funded Research ProgramAntibodies

26 August 2009

GENMAB ANNOUNCES POSITIVE TOP-LINE RESULTS FOR ARZERRA™ IN FRONT LINE NHLAntibodies

24 August 2009

Seattle Genetics Completes Enrollment of Brentuximab Vedotin (SGN-35) Pivotal Trial for Patients with Hodgkin LymphomaAntibodies

24 August 2009

Novartis receives approval in EU for Xolair® to treat children age 6 to 11 years suffering from severe persistent allergic asthmaAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Report Package: Bispecific Antibodies

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount